Can Prestige Biopharma turn HD204 Phase 3 data into a credible Avastin biosimilar launch?
Prestige Biopharma reported positive HD204 Phase 3 data in NSCLC. Read what the bevacizumab biosimilar result could change next.
Pharma & Biotech
Pharma & Biotech
Ustekinumab biosimilar approved in Japan: Can Samsung Bioepis expand its global autoimmune footprint?
Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia's biosimilar adoption. Find out what this means.